AERAS-402

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2010-2016
02420102016

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
The development of a vaccine for Mycobacterium tuberculosis (Mtb) has been impeded by the absence of correlates of protective… (More)
Is this relevant?
2015
2015
BACKGROUND Several novel tuberculosis vaccines are currently in clinical trials, including AERAS-402, an adenovector encoding a… (More)
Is this relevant?
2015
2015
BACKGROUND MVA85A and AERAS-402 are two clinically advanced viral vectored TB vaccine candidates expressing Mycobacterium… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
2014
2014
Development of a vaccine against pulmonary tuberculosis may require immunization strategies that induce a high frequency of Ag… (More)
Is this relevant?
2014
2014
BACKGROUND Efforts to reduce risk of tuberculosis disease in children include development of effective vaccines. Our aim was to… (More)
Is this relevant?
2014
2014
Bacille Calmette-Guérin (BCG), the only licensed vaccine for the prevention of tuberculosis (TB), provides only limited… (More)
Is this relevant?
2012
2012
BACKGROUND Despite the availability of Bacille Calmette Guérin (BCG) vaccines, Mycobacterium tuberculosis currently infects… (More)
Is this relevant?
2012
2012
The trial protocols for diseases common to the developed world now routinely change in midstream in response to real-time… (More)
Is this relevant?
Highly Cited
2010
Highly Cited
2010
RATIONALE AERAS-402 is a novel tuberculosis vaccine designed to boost immunity primed by bacillus Calmette-Guérin (BCG), the only… (More)
Is this relevant?
2010
2010
A powder vaccine intended for aerosol delivery was formulated by spray drying the Ad35-vectored tuberculosis (TB) AERAS-402… (More)
  • figure 1
  • table 1
  • figure 3
  • figure 5
  • figure 7
Is this relevant?